##{"id":60069,"date":"2012-06-07T14:21:52","date_gmt":"2012-06-07T04:21:52","guid":{"rendered":"http:\/\/www.fnarena.com\/index.php\/2012\/06\/07\/amp-value-plus-yield-but-what-about-risk\/"},"modified":"2012-06-07T14:21:52","modified_gmt":"2012-06-07T04:21:52","slug":"amp-value-plus-yield-but-what-about-risk","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2012\/06\/07\/amp-value-plus-yield-but-what-about-risk\/","title":{"rendered":"AMP: Value Plus Yield, But What About Risk?"},"content":{"rendered":"<p>\n\t<strong>&nbsp;&#8211; Morgan Stanley sees value in AMP shares<br \/>\n\t&nbsp;&#8211; Stock is trading around stockbroker&#039;s bear case value<br \/>\n\t&nbsp;&#8211; UBS more cautious given difficult operating conditions<br \/>\n\t&nbsp;&#8211;&nbsp;Capital position also an issue<\/strong><\/p>\n<p>\n\tBy Chris Shaw<\/p>\n<p>\n\tAt current levels, AMP ((AMP)) shares are trading close to Morgan Stanley&#039;s bear case valuation of $3.55 per share. This equates to an earnings multiple of less than 10 times, while the expected yield on the stock is 7.5%, which suggests value at current levels.<\/p>\n<p>\n\tMorgan Stanley&#039;s bear case valuation assumes severe margin compression, net flows below system levels, lower AXA synergies than expected and a fall in growth assets this year of 8% before flat performance in both <span>FY13<\/span> and <span>FY14<\/span>. As well, the broker&#039;s bear case factors in adverse income protection claims and no benefits from the group&#039;s growth options.<\/p>\n<p>\n\tIn Morgan Stanley&#039;s view such an outcome is unlikely, as AMP already cleared the decks of some bad news with its <span>FY11<\/span> result. This supports the broker&#039;s base case, which is for contemporary wealth management net revenue margins to decline to 1.00% in <span>FY16<\/span>, net flows of 5.5% year-on-year and AXA synergies of $150 million. This would support a valuation of $5.40 per share. Even more positive assumptions generate a bull case valuation of $6.70.<\/p>\n<p>\n\tGiven the upside on offer even with respect to its base case valuation, Morgan Stanley rates AMP as Overweight within an In-Line industry view. At current levels the broker suggests AMP is trading as a book in run-off, as marking-to-market the embedded value of AMP&#039;s financial services business delivers a value of $3.54.<\/p>\n<p>\n\tAdding in bearish values for other operations and net shareholder funds generates a value of $4.10. Add in the fact AMP should win its share of large corporate superannuation mandates up for tender, Morgan Stanley sees upside to this run-off valuation.<\/p>\n<p>\n\tWhat should support the share price in coming months are a number of catalysts identified by Morgan Stanley. These include some regulatory finality with respect to <span>MySuper<\/span> expected this month, greater clarity from a regulatory capital review expected in August, positive second quarter net inflows delivering some green shoots in August and a likely clean interim profit result in the same month.&nbsp;<\/p>\n<p>\n\tMorgan Stanley suggests there could be further good news early in <span>FY13<\/span> from synergy upgrades relating to the integration of the AXA business.<\/p>\n<p>\n\tThere are some risks, which include further weakness in global markets, synergies falling short of expected levels and margin weakness in wealth management from increased competition, but in Morgan Stanley&#039;s view these are priced into the stock at current levels.<\/p>\n<p>\n\tA further positive for Morgan Stanley is AMP appears to have enough organic capital capacity to address these potential <span>headwinds<\/span>. This is especially the case as there remains scope for AMP management to more aggressively de-risk AXA to reduce any capital strains or to lower the dividend payout ratio to the lower end of AMP&#039;s target range. This lower end would be a payout ratio of around 70%.<\/p>\n<p>\n\tColleague UBS, however, is not as positive on the outlook for AMP, as evidenced by a Neutral rating on the stock. Market volatility is partly to blame for UBS&#039;s cautious view, as the broker notes market volatility rarely presents positive surprises for life insurance stocks.<\/p>\n<p>\n\tUBS has reviewed its model to account for low fixed interest yields across a range of metrics, with a particular focus on capital and investment earnings. Lower cash rates lead UBS to suggest AMP may struggle to generate <span>anmeaningful<\/span> earnings retention over the next two years.&nbsp;<\/p>\n<p>\n\tWhile AMP should be able to maintain a relatively secure capital position over the next couple of years even allowing for lower earnings retention, there is unlikely to be a large buffer for any adverse outcomes.<\/p>\n<p>\n\tGiven the move to re-base its model for lower cash rates, UBS has trimmed earnings estimates for the insurer\/wealth manager. Earnings per share (EPS) have been trimmed by 3.7% this year and by 3.3% in <span>FY13<\/span> to <span>33c<\/span> and <span>37c<\/span> respectively. This compares to consensus EPS forecasts according to the <span>FNArena<\/span> database of 32.1c and 36.7c respectively, while Morgan Stanley is forecasting underlying EPS of <span>35c<\/span> and <span>39c<\/span>.<\/p>\n<p>\n\tBased on its forecasts UBS has set a price target for AMP of $4.50, which is broadly in line with the consensus target of $4.65. Targets range from Macquarie at $4.22 to BA-Merrill Lynch at $5.20. The database shows AMP is rated as Buy three times and Hold five times.<\/p>\n<p>\n\tCredit Suisse sums up the Neutral argument by noting AMP&#039;s capital position is somewhat tight and market conditions remain <span>unfavourable<\/span>. In contrast, the Buy argument is largely a valuation call, though while BA-ML is one to rate the stock a Buy, the broker cautions there are few short-term catalysts to drive the share price.<\/p>\n<p>\n\tShares in AMP today are stronger in a higher market and as at 11.10am were up 6.5c at $3.845. This compares to a range over the past year of $3.61 to $4.99 and implies upside of around 21% relative to the consensus price target in the <span>FNArena<\/span> database.<\/p>\n<p>\n\t<br \/>\n\t<em>Find out why <span>FNArena<\/span> subscribers like the service so much: &quot;<a href=\"http:\/\/www.fnarena.com\/index4.cfm?type=dsp_newsitem&amp;n=29EB960D-9DFF-C00E-7F6B464E5D52E250\">Your Feedback (Thank You)<\/a>&quot; &#8211; Warning this story contains unashamedly positive feedback on the service provided.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Morgan Stanley&#8217;s view AMP represents value at current levels even allowing for bearish assumptions, but UBS argues a more cautious view is justified.<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[90,91],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/60069"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=60069"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/60069\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=60069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=60069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=60069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}